Yuhan Corporation

Abl Bio Inc.

Yonsei University

Moo Young Song

In Young Ko

Eun-Jung Lee

Jong Wook Lee

Tae Hyoung Yoo

Chang Seok Kim

Sang Koo Park

Heui Keun Kang

Kang In Na

Jae Sun Lee

Heui Il Kang

Byung Hyun Choi

Na Rae Lee

Tae Hyun Song

Young Bong Park

Jung Hyun Nam

Ki Hong Kim

Jong Gyun Kim

Yangsoon Lee

Hyejin Chung

Kyeongsu Park

Jun Hwan Kim

Ui-Jung Jung

In Hwan Lim

Taewang Kim

Yeryoung Yong

Wonjun Son

Byung Kyu Lee

Sung Ho Kim

Hyun Ho Choi

Chang Sik Kim

June Hyung Lee

Ju Young Park

Dohoon Kim

Jong-Seo Lee

Jun Young Park

Hyung Rang Moon

Yeunju Kim

Eunyoung Park

Eunsil Sung

Jin-Hyoung Lee

Youngdon Pak

Donghoon Yeom

Hyung Jo Moon

Yong-Gyu Son

Jaehyun Eom

Seawon Ahn

Minji Park

Eunjung Kim

Jung-Sun Lee

Se Woong Oh

Heui Ii Kang

YoungKwang Kim

Eunjeong Jeong

Hyoju Choi

Bong-Kook Ko

Kyu-Tae Kim

Hyoung Sig Seo

Jin Sook Yoon

Hae Yong Jo

Taejin Yoon

Cheol Ryong Ku

Chanmoo Lee

Junghyeon Hong

Kwang-Hoon Lee

Nakho Chang

Sunghyun Choi

Han Na Hong

Eun Jig Lee

Hyung Jin Moon

Hyeon Woo Kang

Man Sil Park

Tae Hun Song

Jin Hyoung Lee

Se Cheol Park

Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-HER2/anti-4-1BB bispecific antibody and use thereof

Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-EGFR/anti-4-1BB bispecific antibody

A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.

Method for producing dual function proteins and its derivatives

Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition. The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.

Anti-TIGIT antibodies and uses thereof

Disclosed are a fusion protein comprising a thyrotropin receptor (TSHR) fragment and the use thereof. More specifically, disclosed are a fusion protein comprising a TSHR fragment comprising an extracellular domain of a wild-type TSHR and having a substitution of an amino acid at specific position and an immunoglobulin Fc region or a carboxy-terminal cap (C-CAP), and the use thereof. The fusion protein has improved pharmaceutical efficacy, in-vivo persistence and protein stability and a pharmaceutical composition containing the fusion protein as an active ingredient is useful as a therapeutic agent or diagnostic reagent for the alleviation of Graves' disease and Graves' ophthalmopathy.

Fusion protein comprising thyrotropin receptor variants and use thereof

A fusion protein containing a biologically active protein and an FGF21 mutant protein, a pharmaceutical composition containing the fusion protein, and their uses are disclosed. The fusion protein and the pharmaceutical composition are effective in treating a liver disease including hepatitis, hepatic fibrosis, and hepatic cirrhosis. The fusion protein has effects of inhibiting proliferation of inflammatory cells and fibroblasts, and thus can be effectively used for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis.

Pharmaceutical composition containing FGF21 mutant fusion protein and method for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis

Humanized antibodies specifically binding to hTNF-&#x3b1; are prepared from a mouse monoclonal antibody by the CDR (complementarity determining region) grafting method, and they show an antigen binding affinity similar to the original mouse monoclonal antibody and significantly low immunogenicity. Therefore, the humanized antibodies can be effectively used for treating a hTNF-&#x3b1;-related disease such as rheumatoid arthritis, Crohn's disease, psoriatic arthritis, psoriasis, septicemia, asthma, Wegener's granulomatosis, inflammation, and ankylosing spondylitis.

Humanized antibody specific for tumor necrosis factor-alpha

A humanized antibody of the present invention shows similar antigen-binding affinity to a mouse monoclonal antibody and significantly low immunogenecity. Therefore, the humanized antibody of the present invention can be effectively used for treating chronic hepatitis B and preventing HBV infection of a patient received liver transplantation and vertical transmission from a mother infected with HBV to a fetus.

Humanized antibody against S-surface antigen of hepatitis B virus

An antibody variable region of a monoclonal antibody specifically binding to human tumor necrosis factor-&#x3b1; contains at least one of a heavy chain variable region and a light chain variable region having specific complementarity determining regions therein. A nucleic acid molecule encoding the same, a recombinant vector containing the nucleic acid molecule, and a cell transformed with the recombinant vector are also provided.

Antibody variable region of a monoclonal antibody against human tumor necrosis factor alpha and a gene encoding the same

The present invention relates to a variable region of the monoclonal antibody against the S-surface antigen of hepatis B virus and a gene encoding the same, a recombinant vector containing the said gene, and a transformant obtained from the said recombinant vector.

Variable region of the monoclonal antibody against the HBV S-surface antigen and a gene encoding the same

Nucleic acid molecules encoding human tumor necrosis factor &#x3b1;-specific antibodies

The present invention relates to a variable region of the monoclonal antibody against the S-surface antigen of hepatitis B virus and a gene encoding the same, a recombinant vector containing the gene, and a transformant obtained from the recombinant vector.

Variable region of the monoclonal antibody against HBV S-surface antigen and a gene encoding the same

Growing community of inventors

Suwon-si, South Korea

Moo Young Song